PRN: Global Prenatal & Maternal Diagnostic Market Analysis to 2020: Molecular Diagnostics, Liquid Biopsy, Personalized Medicine Diagnostics & In vitro Diagnostics (IVD) Markets

06/gen/2016 16:10:18 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global Prenatal & Maternal Diagnostic Market Analysis to 2020: Molecular Diagnostics, Liquid Biopsy, Personalized Medicine Diagnostics & In vitro Diagnostics (IVD) Markets


DUBLIN, Jan. 6, 2015 /PRNewswire/ --

Research and Markets ( has announced the addition of the "Global Prenatal & Maternal Diagnostic Market Analysis to 2020" report to their offering.

GLOBAL PRENATAL AND MATERNAL DIAGNOSTIC MARKET ANALYSIS indicates that the launch of noninvasive prenatal screening tests (NIPTs) in 2011 dramatically altered the market dynamic, and this sub-section of the market will see an 18% CAGR to 2021. This is at the expense of more invasive techniques as chorionic villus sampling (CVS) or amniocentesis.

A newly published analysis indicates that by 2021, the global prenatal, maternal and newborn screening diagnostic test market will be worth over $10.5 billion, up from $8 billion today. This market is subdivided into ultrasound, fetal MRI, maternal serum and noninvasive prenatal screening technologies and will see a five year compound annual growth rate of 4.1%.

When human genome sequencing was successfully accomplished, experts in the healthcare industry expected that DNA sequencing would mainly focus on genetic diseases in adults. Instead, the impact of sequencing technology has been primarily on prenatal, newborn and preimplantation genetic diagnosis (PGD) tests (prior to in vitro fertilization). In a short span of four years, the different types of maternal serum screening tests and fetal ultrasound tests are getting gradually replaced by the new technology of non-invasive prenatal tests (NIPTs). In the past four years, hundreds and thousands of these new tests have been performed in screening cffDNA from maternal blood.

The objective of this report is to provide an overview of the various technologies being employed for detecting genetic diseases in embryos, fetuses and newborns. The various chapters describe common pregnancy disorders, numerical chromosome disorders and structural chromosome disorders, single gene! disorders inherited by fetuses, newborns and embryos.

The global prenatal and maternal diagnostic test market is assessed with respect to:

  • Fetal Ultrasound
  • Prenatal MRI Screening
  • Maternal Serum Screening Tests
  • Noninvasive Prenatal Tests (NIPTs) using cffDNA
  • NIPTs by Product
  • Prenatal Diagnostic Invasive Tests
  • Newborn Screening for Genetic Diseases
  • Newborn Screening Market by Technology
  • Preimplantation Screening/Diagnosis (PGS/PGD)

SWOT and merger/acquisition analysis is also performed as is a comprehensive documentation of the legislation pertaining to newborn screening by geography and how clinical programs are implemented in developed and developing markets.

Emerging trends in associated markets are also analysed in order to give the reader a comprehensive overview of how prenatal and maternal diagnostic testing is affected by the following industries:

  • Molecular Diagnostics Market
  • Liquid Biopsy Market
  • Personalized Medicine Diagnostics Market
  • In vitro Diagnostics (IVD) Market

Key Topics Covered:

1.0 Introduction

2.0 Prenatal Pregnancy Complications: An Overview

3.0 Types of Genetic Diseases in Fetuses: An Overview

4.0 Genetic Counseling: An Overview

5.0 Prenatal Screening for Genetic Diseases: An Overview

6.0 Newborn Screening

7.0 Preimplantation Genetic Screening & Genetic Diagnosis (PGS/PGD)

8.0 Pregnancy, Prenatal, Newborn and PGD-Related Technologies: An Overview

9.0 Prenatal Screening and Diagnostics: Market Overview

10.0 Other Genetic Testing-Related Markets

11.0 Market SWOT and Strategy Analysis

12.0 Company Profiles - 30 of the 114 Companies Featured in this Extensive Report

  1. - 23andMe Inc.
  2. - Abbott Laboratories
  3. - Abbott Molecular Inc.
  4. - Abcam plc
  5. - AB Sciex LLC
  6. - Adaltis S.r.l
  7. - Adaptive Biotechnologies Corp.
  8. - Affymetrix Inc.
  9. - Agena Biosciences Inc.
  10. - Agilent Technologies Inc.
  11. - Ambry Genetics Corp.
  12. - Analogic Corp.
  13. - Ariosa Diagnostics Inc.
  14. - Ansh Labs
  15. - Appistry Inc.
  16. - ARUP Laboratories
  17. - AssureRx Health Inc.
  18. - Asuragen Inc.
  19. - Athena Diagnostics Inc.
  20. - AutoGenomics Inc.
  21. - Base4 Innovation Ltd.
  22. - Beckman Coulter Inc.
  23. - Berry Genomics Co., Ltd.
  24. - Bina Technologies Inc.
  25. - Bio-Rad (Israel) Laboratories Inc.
  26. - BGI
  27. - Blueprint Genetics Oy
  28. - Boreal Genomics Inc.
  29. - Cambridge Epigenetix Ltd.
  30. - Claris Lifesciences

For more information visit

Media Contact: Laura Wood , +353-1-481-1716,

blog comments powered by Disqus è un servizio offerto da Factotum Srl